Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005542 | 0.85 | XDH (0.44) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL19504515 | 0.83 | CYP11B1 (0.40) | CYP1A1CYP1B1CYP11B1CYP11B2MKNK2 | |
| SCHEMBL22338687 | 0.83 | CYP11B1 (0.44) | CYP1A1CYP1B1CYP11B1CYP11B2MKNK2 | |
| SCHEMBL27795957 | 0.83 | CYP11B1 (0.44) | CYP1A1CYP1B1CYP11B1CYP11B2MKNK2 | |
| SCHEMBL2202031 | 0.81 | CYP11B1 (0.49) | CYP1A1CYP1B1CYP11B1CYP11B2MKNK2 | |
| SCHEMBL22302832 | 0.80 | CYP11B1 (0.45) | CYP1A1CYP1B1CYP11B1CYP11B2MKNK2 | |
| SCHEMBL19251170 | 0.80 | CYP11B1 (0.38) | CYP1A1CYP1B1CYP11B1CYP11B2MKNK2 | |
| SCHEMBL21424457 | 0.79 | CYP11B1 (0.37) | CYP1A1CYP1B1CYP11B1CYP11B2MKNK2 | |
| SCHEMBL744752 | 0.78 | CYP1A1 (0.61) | CYP1A1CYP1B1CYP11B1CYP11B2MKNK2 | |
| SCHEMBL823824 | 0.78 | GABRA1 (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | Pelemed Co., Ltd. (UA) | 2023-12-14 | — | — | US | disclosed |
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | Pelemed Co., Ltd. (UA) | 2023-12-14 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| EP-3611165-B1 | PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT | MITSUI CHEMICALS CROP & LIFE SOLUTIONS INC (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20070293508-A1 | Crf Receptor Antagonists and Methods Relating Thereto | SB PHARMCO PUERTO RICO INC AND NEUROCRINE BIOSCIENCES, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | CYP1A1 67/4885CYP1B1 34/4885CYP11B1 24/4885 |
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | CYP1A1 1944/4885CYP1B1 560/4885CYP11B1 690/4885 |
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | PDE12, PDE5A, PDE3A | CYP1A1 225/4885CYP1B1 118/4885CYP11B1 87/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | CYP1A1 191/4885CYP1B1 264/4885CYP11B1 53/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP1A1 1436/4885CYP1B1 1266/4885CYP11B1 1560/4885 |
| US-20090197877-A1 | Antibacterial Compositions | CYCS, COX6C, INTS6 | CYP1A1 396/4885CYP1B1 673/4885CYP11B1 1639/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | CYP1A1 774/4885CYP1B1 1414/4885CYP11B1 367/4885 |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | CYP1A1 1944/4885CYP1B1 560/4885CYP11B1 690/4885 |
| US-20070293508-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, SCTR | CYP1A1 885/4885CYP1B1 1432/4885CYP11B1 399/4885 |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | PDE2A, PDE5A, PDE3A | CYP1A1 49/4885CYP1B1 88/4885CYP11B1 536/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | CYP1A1 4155/4885CYP1B1 3928/4885CYP11B1 3938/4885 |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | ALOX5, ALOX15, LTB4R2 | CYP1A1 373/4885CYP1B1 460/4885CYP11B1 371/4885 |
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | ZC3HAV1, COPB1, CNBP | CYP1A1 4612/4885CYP1B1 4593/4885CYP11B1 4793/4885 |
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | PDE2A, PDE5A, PDE12 | CYP1A1 515/4885CYP1B1 488/4885CYP11B1 419/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CYP1A1 1001/4885CYP1B1 1277/4885CYP11B1 1168/4885 |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | APLNR, AGTR1, AGTR2 | CYP1A1 1356/4885CYP1B1 1075/4885CYP11B1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.